Navigation Links
Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
Date:1/5/2011

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the 29th Annual J.P. Morgan Healthcare Conference to be held on January 9-13, 2011 in San Francisco. Gregory Frost, Ph.D., president and CEO, will present an overview of Halozyme's business strategy and its product development pipeline on Wednesday, January 12, 2011 at 3:30 p.m. PST (6:30 p.m. EST). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, and with Baxter Bi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... -- Packaging Coordinators, Inc. (PCI) is pleased to announce it ... Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... United Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug ... form manufacturing, as well as Clinical Packaging, Labeling, and ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... imaging,(BSGI) is effective in the detection of cancers not ... study presented today at the annual meeting of,the Radiological ... "BSGI can identify the most difficult ... F. Brem, M.D., professor of,radiology and director of the ...
... Horizon Therapeutics, Inc., a,privately held biopharmaceutical ... 3 trials evaluating its lead investigational ... HZT-501, a novel, proprietary fixed-dose,combination product ... significant reduction in the incidence of ...
Cached Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4
(Date:7/30/2014)... 30, 2014 Hamilton Facial Plastic ... its new Carmel office on July 30th. After months ... be moving to the state-of-the-art suite, located only steps ... space will allow for one-on-one patient comfort, shorter wait ... , Dr. Hamilton’s new office-suite will continue to ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
(Date:7/30/2014)... July 30, 2014 The Technology Association ... Alliance of TAG (B&TA), today issued its final call ... Awards. , Interested companies have until August 29th 2014 ... Semi-Finalists will be selected by the Excalibur Judging Committee. ... meet with the judges for interviewing process. , ...
(Date:7/30/2014)... 2014 Over 630 doctors worldwide are ... the revolutionary minimally invasive treatment for gum recession. Santa ... of his peers to be the “father of microsurgery” ... recent Chao Pinhole Surgical Technique® training course at the ... the recipient of the American Academy of Periodontics (AAP) ...
Breaking Medicine News(10 mins):Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2
... the form of a throat spray, researchers say , TUESDAY, ... may someday be able to avoid a tonsillectomy and get ... potentially dangerous snoring, new research suggests. , In a report ... Respiratory and Critical Care Medicine , researchers say that they,ve ...
... ... Human Services uses Percussion Community Marketing Solution to implement President Obama’s Open Government ... ... Health and Human Services is using Percussion Software’s Web Content Management System and ...
... , , SAN DIEGO , Feb. 10 ... dreams are attainable.  Back in the third quarter of 2006, 62% of ... achieving their personal dreams.  Now 55% of Americans feel this way.  On ... chance or it is impossible for them to achieve their dreams – ...
... Lou ... President of Product Marketing. , ... Charlottesville, VA (PRWEB) Feb. 29, 2010 -- Silverchair Learning Systems (SLS), the leading online education ... Robinson has joined the company as its Director of Home Health Clinical Content, and Vince ...
... ... has received a two-year grant from Merck & Co., Inc. to launch the Journey ... the EDGE Program is to improve diabetes education by enhancing the role of state ... Diabetes Conversation Maps. , ...
... , ... network announces a limited offering of free listings on its popular values-based therapist directory. ... on the directory is limited and the offering expires February 19th, 2010. , ... Olympia, WA (PRWEB) February 10, 2010 -- ...
Cached Medicine News:Health News:Web Content Management Enables Government Transparency, Participation, and Collaboration Online 2Health News:Web Content Management Enables Government Transparency, Participation, and Collaboration Online 3Health News:Web Content Management Enables Government Transparency, Participation, and Collaboration Online 4Health News:Luth Research's IndicatorEDG(TM) Study Finds Americans' Hopes of Achieving Their Dreams Are Fading 2Health News:Luth Research's IndicatorEDG(TM) Study Finds Americans' Hopes of Achieving Their Dreams Are Fading 3Health News:Luth Research's IndicatorEDG(TM) Study Finds Americans' Hopes of Achieving Their Dreams Are Fading 4Health News:Silverchair Learning Systems Enhances Product Expertise with New Hires 2Health News:NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education 2Health News:NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education 3Health News:Theravive.com Offers A Free Therapist Listing For Credentialed Counselors and Psychologists 2Health News:Theravive.com Offers A Free Therapist Listing For Credentialed Counselors and Psychologists 3
... Focus multichannel pipettes speed ... reagents into microplates, with ... l volumes. The improved ... Focus multichannels, combined with ...
... rows, and microplatesthat is the area of ... becoming an ever-increasing force. Ergonomics (reduced weight ... reason that the Multichannel Research model was ... provides effective, precise, and rapid processing of ...
... Hall, the aortic and mitral valves are distinctly ... the disc opens to 75 to maximize forward ... to minimize regurgitation. Designed to rotate within its ... the leading edge of the disc parallel to ...
Inquire...
Medicine Products: